We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ONWRF market cap is 207.77M. The company's latest EPS is EUR -1.0448 and P/E is -5.69.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 554k | 800k | 1.4M | 2.15M | 532k |
| Operating Income | -10.77M | -15.51M | -28.53M | -32.03M | -35.46M |
| Net Income | -13.48M | -20.01M | -34.31M | -32.77M | -36.18M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 23.35M | 14.19M | 104.8M | 76.59M | 43.63M |
| Total Liabilities | 38.27M | 46.29M | 22.11M | 23.96M | 25.7M |
| Total Equity | -14.92M | -32.1M | 82.68M | 52.63M | 17.93M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -9.85M | -12.9M | -19.88M | -26.69M | -32.27M |
| Investing | -99k | -173k | -2.32M | -20.42M | 19.58M |
| Financing | 16.4M | 4.37M | 105.36M | -557k | 813k |
| Market Cap | 207.77M |
| Price to Earnings Ratio | -5.69 |
| Price to Sales Ratio | 386.36 |
| Price to Cash Ratio | 6.92 |
| Price to Book Ratio | 11.49 |
| Dividend Yield | - |
| Shares Outstanding | 34.63M |
| Average Volume (1 week) | 1.71k |
| Average Volume (1 Month) | 1.01k |
| 52 Week Change | 0.33% |
| 52 Week High | 7.13 |
| 52 Week Low | 4.81 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Onward Medical NV (CE) |
| Address |
high tech campus 32 eindhoven, north brabant 5656 AE |
| Website | https://www.onwd.com |
| Industry | medical laboratories (8071) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
